Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H2O2-induced oxidative damage in PC12 cells.

Product information

CAS Number: 80418-24-2

Molecular Weight: 933.13

Formula: C47H80O18

Synonym:

Sanchinoside R1

Sanqi glucoside R1

Chemical Name: (2S, 3R, 4S, 5S, 6R)-2-{[(2S)-2-[(1S, 3aR, 3bR, 5S, 5aR, 7S, 9aR, 9bR, 11R, 11aR)-5-{[(2R, 3R, 4S, 5S, 6R)-4, 5-dihydroxy-6-(hydroxymethyl)-3-{[(2S, 3R, 4S, 5R)-3, 4, 5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-7, 11-dihydroxy-3a, 3b, 6, 6, 9a-pentamethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-en-2-yl]oxy}-6-(hydroxymethyl)oxane-3, 4, 5-triol

Smiles: CC1(C)[C@@H]2[C@H](C[C@]3(C)[C@H](C[C@@H](O)[C@@H]4[C@H](CC[C@@]34C)[C@](C)(CCC=C(C)C)O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@]2(C)CC[C@@H]1O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O

InChiKey: LLPWNQMSUYAGQI-OOSPGMBYSA-N

InChi: InChI=1S/C47H80O18/c1-21(2)10-9-13-47(8,65-41-37(59)34(56)32(54)26(18-48)62-41)22-11-15-45(6)30(22)23(50)16-28-44(5)14-12-29(52)43(3,4)39(44)25(17-46(28,45)7)61-42-38(35(57)33(55)27(19-49)63-42)64-40-36(58)31(53)24(51)20-60-40/h10,22-42,48-59H,9,11-20H2,1-8H3/t22-,23+,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34-,35-,36+,37+,38+,39-,40-,41-,42+,44+,45+,46+,47-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 100 mg/mL (107.17 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Notoginsenoside R1 (2.5-80 μM; 24 h) inhibits the hypoxia-reoxygenation (H/R)-induced cell death, intracellular ROS accumulation, and mitochondrial membrane depolarization in H9c2 cardiomyocytes. Notoginsenoside R1 (5-20 μM; 24 h) inhibits the H/R-induced H9c2 cardiomyocytes apoptosis in a concentration-dependent manner. Notoginsenoside R1 (1-100 μM; 24 h) dose-dependently protects PC12 cells and primary neurons from Aβ-induced cell death and apoptosis. Notoginsenoside R1 (10 μM; 24 h) inhibits Aβ25-35-induced ROS production, mitochondrial damage and MAPK activation in PC12 cells.

In Vivo:

Notoginsenoside R1 (5 mg/kg/h; infused via the right jugular vein) increases red blood cell velocity, reduces the number of adherent leukocytes and inhibits mast cell degranulation and cytokine elevation in rats.

References:

1. Yu Y, et, al. Cardioprotective effects of Notoginsenoside R1 against ischemia/reperfusion injuries by regulating oxidative stress- and endoplasmic reticulum stress- related signaling pathways. Sci Rep. 2016 Feb 18;6:21730.
2. Ma B, et, al. Notoginsenoside R1 attenuates amyloid-β-induced damage in neurons by inhibiting reactive oxygen species and modulating MAPK activation. Int Immunopharmacol. 2014 Sep;22(1):151-9.
3. Sun K, et, al. Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. Life Sci. 2007 Jul 19;81(6):509-18.

Products are for research use only. Not for human use.